Amanta Healthcare Limited
NSE: AMANTA · Pharmaceuticals · sector
₹166.85NSE close 2026-10-26
Key numbers
Market cap₹574 cr
Price₹166.85
52w high / low₹210 / ₹92
P/E40.1xSector median 27.9x
P/B2.6xSector median 2.9x
Book value₹64.0
Dividend yield0.07%Sector median 0.48%
ROE6.7%Sector median 11.7%
ROCE9.1%Sector median 12.3%
OPM19.5%Sector median 14.0%
Debt / equity1.06xSector median 0.16x
EV/EBITDA12.6xSector median 18.6x
Interest cover2.0x
Current ratio1.69x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹93 cr vs borrowings ₹234 cr (FY26): borrowings are higher by ₹142 cr.
- Operating profit covered interest 2.0x in the last 12 months.
- Other income was 21% of net profit in the last 12 months.
- No dividend in the last 1 financial years.
- Price ₹166.85 on 2026-10-26: -20.5% from the 52-week high, +81.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹205.89 · low ₹96.41
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 65 | 71 | 74 | 77 | 69 |
| EBITDA | 15 | 12 | 15 | 15 | 15 |
| OPM % | 22.8% | 17.0% | 20.6% | 19.4% | 21.1% |
| Other income | 1 | 0 | 1 | 2 | 1 |
| Net profit | 4 | 1 | 5 | 6 | 3 |
| EPS (₹) | 1.22 | 0.35 | 1.35 | 1.61 | 0.85 |
| Revenue YoY | +5.3% | ||||
| Profit YoY | -5.7% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY26 | TTM |
|---|---|---|
| Revenue | 288 | 291 |
| EBITDA | 57 | 57 |
| Net profit | 15 | 15 |
| EPS (₹) | 4.33 | 4.16 |
| Dividend / share (₹) | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | +26.1% |
Balance sheet
| ₹ cr | FY26 |
|---|---|
| Shareholders' equity | 220 |
| Borrowings | 234 |
| Cash & equivalents | 93 |
| Total assets | 558 |
| Fixed assets | 197 |
| Capital work in progress | 82 |
| Investments | 7 |
| Receivables | 43 |
| Inventory | 83 |
| Payables | 36 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY26 |
|---|---|
| Cash from operations | 48 |
| Cash from investing | -94 |
| Cash from financing | 126 |
| Capex | 80 |
| Free cash flow | -32 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY26 |
|---|---|
| ROE % | 6.8% |
| ROCE % | 9.2% |
| Debtor days | 55 |
| Inventory days | 312 |
| Payable days | 136 |
| Cash conversion cycle (days) | 231 |
| Working capital days | 123 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 63.80% |
| FIIs | 0.07% |
| DIIs | 12.20% |
| of which Mutual funds | 5.12% |
| Public (non-institutions) | 23.93% |
| Quarter | Sep 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| Promoters % | 63.56% | 63.56% | 63.56% | 63.72% | 63.80% | 63.80% |
| Promoter group | % |
|---|---|
| Bhavesh Girishbhai Patel | 16.31% |
| Vishal Ashokkumar Patel | 10.06% |
| Jitendrakumar Jashbhai Patel | 9.02% |
| Milcent Appliances Private Limited | 7.98% |
| Praful Jashbhai Patel | 5.88% |
| Shailesh Mansukhlal Mehta | 4.46% |
| Niranjanbhai Ishwarbhai Patel | 3.88% |
| Kirit Ambalal Desai | 3.29% |
| Jayshreeben Rohitkumar Patel | 2.57% |
| Pravinchandra Dhanjibhai Mehta | 0.26% |
| Darpana J. Patel | 0.06% |
| Sarala Kirit Desai | 0.03% |
| Jatin Kumar J Mehta | 0.01% |
| Manisha B Patel | 0.00% |
| Pramilaben Patel | 0.00% |
| Public holders above 1% | % |
|---|---|
| Bandhan Small Cap Fund | 5.12% |
| Finavenue Capital Trust - Finavenue Growth Fund | 1.86% |
| Perpetuity Health To Wealth (H2w) Rising Fund | 1.83% |
| Aarth Aif Growth Fund | 1.57% |
12,319 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| AMANTA | ₹574 cr | 40.1x | 2.6x | 6.7% | 9.1% | 19.5% | – | 0.07% |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | AMANTA |
| BSE code | 544502 |
| ISIN | INE084K01015 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.